With the TNBC/lerolimab trial, I believe ccr5 expression in measured with a biopsy
Here was a method they used to automate her 2 expression with ctcs.
Quantifying HER-2 expression on circulating tumor cells by ACCEPT.
Abstract
They presented a her2/ccr5 link with ctcs recently, but I have yet to find the poster to see how they determined the ccr5 expression with ctcs..
https://twitter.com/MCristofanill/status/1112363311415345155
https://twitter.com/LGerratana/status/1112250580334985217
https://ativsoftware.com/appinfo.php?page=Int...mp;id=4723
http://www.siliconbiosystems.com/press-releas...ast-cancer
Quote:2) Demonstrate CCR5 + by IHC (>10% membranous staining completed at the reference laboratory of Dr. Hallgeir Rui at Medical College of Wisconsin).
Note: This test will be done as part of the pre-screening period. It will be performed in archival metastatic tissue. If archival tissue is not available then, fresh biopsy will be done;
3)Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion (in case archival tissue is not available);
Here was a method they used to automate her 2 expression with ctcs.
Quantifying HER-2 expression on circulating tumor cells by ACCEPT.
Abstract
Quote:
Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment targets. Immunofluorescence is often used for both the enumeration of CTC and the determination of protein expression levels related to treatment targets. Accurate and reproducible assessment of such treatment target expression levels is essential for their use in the clinic. To enable this, an open source image analysis program named ACCEPT was developed in the EU-FP7 CTCTrap and CANCER-ID programs. Here its application is shown on a retrospective cohort of 132 metastatic breast cancer patients from which blood samples were processed by CellSearch® and stained for HER-2 expression as additional marker. Images were digitally stored and reviewers identified a total of 4084 CTCs. CTC's HER-2 expression was determined in the thumbnail images by ACCEPT. 150 of these images were selected and sent to six independent investigators to score the HER-2 expression with and without ACCEPT. Concordance rate of the operators' scoring results for HER-2 on CTCs was 30% and could be increased using the ACCEPT tool to 51%. Automated assessment of HER-2 expression by ACCEPT on 4084 CTCs of 132 patients showed 8 (6.1%) patients with all CTCs expressing HER-2, 14 (10.6%) patients with no CTC expressing HER-2 and 110 (83.3%) patients with CTCs showing a varying HER-2 expression level. In total 1576 CTCs were determined HER-2 positive. We conclude that the use of image analysis enables a more reproducible quantification of treatment targets on CTCs and leads the way to fully automated and reproducible approaches.
They presented a her2/ccr5 link with ctcs recently, but I have yet to find the poster to see how they determined the ccr5 expression with ctcs..
https://twitter.com/MCristofanill/status/1112363311415345155
https://twitter.com/LGerratana/status/1112250580334985217
Quote:#CCR5 and #HER2 as #CTC based #circulating #biomarkers. New insights on #metastatic #BreastCancer #biology and promising new #therapeutic targets this afternoon at board 10, section 17 #CTC #MBC #PrecisionMedicine #AACR19
https://ativsoftware.com/appinfo.php?page=Int...mp;id=4723
http://www.siliconbiosystems.com/press-releas...ast-cancer
